Drug intelligence / Profile preview

ANTIGN-109

Development stage: Preclinical
Lead developer: Protheragen
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous, Subcutaneous, Intramuscular

Overview

ANTIGN-109 is a monoclonal antibody targeting the gonadotropin-releasing hormone receptor (GnRHR), currently in preclinical development by Protheragen for the treatment of cancer. GnRHR is a G protein-coupled receptor primarily known for its role in the hypothalamic-pituitary-gonadal axis, but it is also expressed in various peripheral malignancies, including breast, prostate, and ovarian cancers. By targeting GnRHR, ANTIGN-109 aims to inhibit tumor growth through direct signaling interference or by leveraging antibody-dependent cellular cytotoxicity (ADCC) against GnRHR-positive malignant cells.

Targets

GnRHR (Gonadotropin-releasing hormone receptor)

Beyond the preview

Go deeper on ANTIGN-109.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ANTIGN-109.

Explore the full profile